Moderna remains in a precarious transition phase—from COVID-revenue dependency toward a diversified vaccine portfolio. Technically, momentum favors upside in the short-term, but fundamentals and macro-regulatory factors suggest caution. If its RSV and flu/COVID combo rollouts succeed and regulatory support stabilizes, it could rebound toward analyst targets near 60. Otherwise, expect choppier consolidation or downward pressure.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.